Summary of COVID-19 sentinox studies

1. Panatto et al., Efficacy of the Sentinox Spray in Reducing Viral Load in Mild COVID-19 and Its Virucidal Activity against Other Respiratory Viruses: Results of a Randomized Controlled Trial and an In Vitro Study

57 patient sentinox early treatment RCT: 67% lower progression (p=0.32) and 29% improved viral clearance (p=0.01).
RCT 57 mild COVID-19 patients showing non-significant viral load reduction with Sentinox (STX), a hypochlorous acid nasal spray. The proportion of COVID negative patients by day 5 was significantly higher in the STX-3 group than controls. Authors note that the results were likely driven by outliers with extreme baseline viral loads. When considering subjects with baseline cycle threshold values of 20-30, STX-3 showed a significant 2.01 log10 reduction. A complementary in vitro study demonstrated STX had ≥99.9% virucidal activity against various respiratory viruses including influenza, RSV, rhinovirus, adenovirus, parainfluenza, and seasonal coronavirus.
May 2022, Viruses, https://www.mdpi.com/1999-4915/14/5/1033, https://c19p.org/panatto